Literature DB >> 26953223

Inter-Observer Variation in the Pathologic Identification of Minimal Extrathyroidal Extension in Papillary Thyroid Carcinoma.

Henry K Su1, Bruce M Wenig2, Grace C Haser1, Meghan E Rowe1, Sylvia L Asa3, Zubair Baloch4, Eugenie Du5, William C Faquin6, Giovanni Fellegara7, Thomas Giordano8, Ronald Ghossein9, Virginia A LiVolsi4, Ricardo Lloyd10, Ozgur Mete3, Umut Ozbek11, Juan Rosai7, Saul Suster12, Lester D Thompson13, Andrew T Turk14, Mark L Urken15.   

Abstract

BACKGROUND: Extrathyroidal extension (ETE) is a significant prognostic factor in papillary thyroid carcinoma (PTC). Minimal extrathyroidal extension (mETE) is characterized by involvement of the sternothyroid muscle or perithyroid soft tissue, and is generally identified by light microscope examination. Patients with mETE, identified pathologically, are automatically upstaged to pT3. However, the prognostic implications of mETE have been a source of controversy in the literature. Moreover, there is also controversy surrounding the identification of mETE on pathological specimens. The objective of this study was to determine the level of agreement among expert pathologists in the identification of mETE in PTC cases.
METHODS: Eleven expert pathologists from the United States, Italy, and Canada were asked to perform a review of 69 scanned slides of representative permanent sections of PTC specimens. Each slide was evaluated for the presence of mETE. The pathologists were also asked to list the criteria they use to identify mETE.
RESULTS: The overall strength of agreement for identifying mETE was slight (κ = 0.14). Inter-pathologist agreement was best for perithyroidal skeletal muscle involvement (κ = 0.46, moderate agreement) and worst for invasion around thick-walled vascular structures (κ = 0.02, slight agreement). In addition, there was disagreement over the constellation of histologic features that are diagnostic for mETE, which affected overall agreement for diagnosing mETE.
CONCLUSIONS: Overall agreement for the identification of mETE is poor. Disagreement is a result of both variation in individual pathologists' interpretations of specimens and disagreement on the histologic criteria for mETE. Thus, the utility of mETE in staging and treatment of PTC is brought into question. The lack of concordance may explain the apparent lack of agreement regarding the prognostic significance of this pathologic feature.

Entities:  

Mesh:

Year:  2016        PMID: 26953223      PMCID: PMC5583558          DOI: 10.1089/thy.2015.0508

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  16 in total

1.  Minimal extrathyroid extension does not affect the relapse-free survival of patients with papillary thyroid carcinoma measuring 4 cm or less over the age of 45 years.

Authors:  Yasuhiro Ito; Chisato Tomoda; Takashi Uruno; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

2.  Extrathyroid spread in papillary carcinoma of the thyroid: clinicopathological and prognostic study.

Authors:  S Ortiz; J M Rodríguez; T Soria; D Pérez-Flores; A Piñero; J Moreno; P Parrilla
Journal:  Otolaryngol Head Neck Surg       Date:  2001-03       Impact factor: 3.497

3.  Extrathyroidal extension predicts extranodal extension in patients with positive lymph nodes: an important association that may affect clinical management.

Authors:  Jason B Clain; Sophie Scherl; Laura Dos Reis; Andrew Turk; Bruce M Wenig; Saral Mehra; William E Karle; Mark L Urken
Journal:  Thyroid       Date:  2014-05-05       Impact factor: 6.568

4.  A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group.

Authors:  D P Byar; S B Green; P Dor; E D Williams; J Colon; H A van Gilse; M Mayer; R J Sylvester; M van Glabbeke
Journal:  Eur J Cancer       Date:  1979-08       Impact factor: 9.162

5.  Prognostic factors in well-differentiated thyroid carcinoma.

Authors:  Sharon L Cushing; Carsten E Palme; Nathalie Audet; Spiro Eski; Paul G Walfish; Jeremy L Freeman
Journal:  Laryngoscope       Date:  2004-12       Impact factor: 3.325

Review 6.  Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension.

Authors:  Ozgur Mete; Lorne Rotstein; Sylvia L Asa
Journal:  Ann Surg Oncol       Date:  2009-12-01       Impact factor: 5.344

7.  Extrathyroid extension of well-differentiated papillary thyroid microcarcinoma on US.

Authors:  Jin Young Kwak; Eun-Kyung Kim; Ji Hyun Youk; Min Jung Kim; Eun Ju Son; Seon Hyeong Choi; Ki Keun Oh
Journal:  Thyroid       Date:  2008-06       Impact factor: 6.568

8.  Locally invasive papillary thyroid carcinoma: 1940-1990.

Authors:  T V McCaffrey; E J Bergstralh; I D Hay
Journal:  Head Neck       Date:  1994 Mar-Apr       Impact factor: 3.147

9.  Locally invasive, well-differentiated thyroid cancer. 22 years' experience at Memorial Sloan-Kettering Cancer Center.

Authors:  H S Cody; J P Shah
Journal:  Am J Surg       Date:  1981-10       Impact factor: 2.565

10.  Differentiated carcinoma of the thyroid with extrathyroidal extension.

Authors:  P E Andersen; J Kinsella; T R Loree; A R Shaha; J P Shah
Journal:  Am J Surg       Date:  1995-11       Impact factor: 2.565

View more
  14 in total

Review 1.  Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management.

Authors:  B Xu; R Ghossein
Journal:  Eur J Surg Oncol       Date:  2017-05-18       Impact factor: 4.424

2.  Thyroglossal Duct Cyst Carcinomas: A Clinicopathologic Series of 22 Cases with Staging Recommendations.

Authors:  Lester D R Thompson; Hannah B Herrera; Sean K Lau
Journal:  Head Neck Pathol       Date:  2016-10-04

Review 3.  Crucial parameters in thyroid carcinoma reporting - challenges, controversies and clinical implications.

Authors:  Bin Xu; Ronald A Ghossein
Journal:  Histopathology       Date:  2018-01       Impact factor: 5.087

Review 4.  [Definition of R1 resection in thyroid carcinoma].

Authors:  S Synoracki; Ch Wittekind; H Dralle; K W Schmid
Journal:  Chirurg       Date:  2017-09       Impact factor: 0.955

5.  Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system.

Authors:  N Chereau; T O Oyekunle; A Zambeli-Ljepović; H S Kazaure; S A Roman; F Menegaux; J A Sosa
Journal:  Br J Surg       Date:  2019-04-23       Impact factor: 6.939

6.  Minimal extrathyroid extension in papillary micro carcinoma of the thyroid is an independent risk factor for relapse through lymph node and distant metastases.

Authors:  Robert Seifert; Michael Andreas Schäfers; Barbara Heitplatz; Laura Kerschke; Burkhard Riemann; Benjamin Noto
Journal:  J Nucl Med       Date:  2021-03-26       Impact factor: 11.082

Review 7.  [Proposal for an extended pTNM classification of thyroid carcinoma : Commentary on deficits of the 8th edition of the TNM classification (German version)].

Authors:  K W Schmid; S Synoracki; H Dralle; C Wittekind
Journal:  Pathologe       Date:  2018-02       Impact factor: 1.011

8.  Histopathological analysis of papillary thyroid carcinoma detected during ultrasound screening examinations in Fukushima.

Authors:  Shinichi Suzuki; Tetiana I Bogdanova; Vladimir A Saenko; Yuko Hashimoto; Masahiro Ito; Manabu Iwadate; Tatiana I Rogounovitch; Mykola D Tronko; Shunichi Yamashita
Journal:  Cancer Sci       Date:  2019-01-20       Impact factor: 6.716

9.  Identification of Hürthle cell cancers: solving a clinical challenge with genomic sequencing and a trio of machine learning algorithms.

Authors:  Yangyang Hao; Quan-Yang Duh; Richard T Kloos; Joshua Babiarz; R Mack Harrell; S Thomas Traweek; Su Yeon Kim; Grazyna Fedorowicz; P Sean Walsh; Peter M Sadow; Jing Huang; Giulia C Kennedy
Journal:  BMC Syst Biol       Date:  2019-04-05

Review 10.  Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting.

Authors:  Ronald Ghossein; Justine A Barletta; Martin Bullock; Sarah J Johnson; Kennichi Kakudo; Alfred K Lam; Mufaddal T Moonim; David N Poller; Giovanni Tallini; R Michael Tuttle; Bin Xu; Anthony J Gill
Journal:  Hum Pathol       Date:  2020-09-10       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.